Paper
Document
Submit new version
Download
Flag content
24

Caspase-8 has dual roles in regulatory T cell homeostasis balancing immunity to infection and collateral inflammatory damage

Authors
Charis E. Teh,Simon P. Preston
Alissa K. Robbins,Michael D. Stutz,James Cooney,Michelle P. Clark,Antonia N. Policheni,Cody C. Allison,Liana Mackiewicz,Philip Arandjelovic,Gregor Ebert,Marcel Doerflinger,Tania Tan,Lucille C. Rankin,Peggy P. Teh,Gabrielle T. Belz,Axel Kallies,Andreas Strasser,Marc Pellegrini,Daniel H. D. Gray,Charis Teh,Simon Preston,Alissa Robbins,Michael Stutz,Michelle Clark,Antonia Policheni,Cody Allison,Lucille Rankin,Peggy Teh,Gabrielle Belz
+28 authors
,Daniel Gray
Published
Mar 25, 2022
Show more
Save
TipTip
Document
Submit new version
Download
Flag content
24
TipTip
Save
Document
Submit new version
Download
Flag content

Abstract

Targeting the potent immunosuppressive properties of FOXP3+ regulatory T cells (Tregs) has substantial therapeutic potential for treating autoimmune and inflammatory diseases. Yet, the molecular mechanisms controlling Treg homeostasis, particularly during inflammation, remain unclear. We report that caspase-8 is a central regulator of Treg homeostasis in a context-specific manner that is decisive during immune responses. In mouse genetic models, targeting caspase-8 in Tregs led to accumulation of effector Tregs resistant to apoptotic cell death. Conversely, inflammation induced the MLKL-dependent necroptosis of caspase-8-deficient lymphoid and tissue Tregs, which enhanced immunity to a variety of chronic infections to promote clearance of viral or parasitic pathogens. However, improved immunity came at the risk of lethal inflammation in overwhelming infections. Caspase-8 inhibition using a clinical-stage compound revealed that human Tregs have heightened sensitivity to necroptosis compared with conventional T cells. These findings reveal a fundamental mechanism in Tregs that could be targeted to manipulate the balance between immune tolerance versus response for therapeutic benefit.

Paper PDF

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.